Rochester-based iCardiac Technologies announced its sales jumped 76% over the past year. iCardiac provides drug development companies worldwide with the complete range of next generation cardiac safety core lab services. Its team of cardiac safety experts collectively bring over 100 years of cardiology, electrophysiology, drug development, regulatory and academic experience. According to iCardiac’s CEO, Mikael Totterman, “The revenue growth in 2010 represents the fastest revenue growth experienced in the history of the company and reflects the rapid market adoption of iCardiac’s unique solutions.â€
iCardiac’s core technology emerged from research conducted at the University of Rochester. iCardiac investors include the Rochester-based venture capital firm Trillium Group.
